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ABSTRACT 
Introduction: It has been well established and evidence-based 
fact that serum levels of  proteins, cholesterol, trace elements, and 
pseudouridines may suffer changes during a neoplastic disease pro-
cess. This report encompassed four prospective studies, original in 
Iraq to our knowledge, had explored the serum total proteins (TP), 
pseudouridines levels, total serum cholesterol (TSC), and serum 
trace elements (TE), in groups of  patients harboring primary brain 
tumours (PBT) compared to healthy persons. Patients and Meth-
ods:Study number 1: A group of  107 patients, from both sexes, 
aged 2-75 years,  harboring PBT were admitted to and operated 
upon via formal craniotomy by staff   neurosurgeons at The Teach-
ing Hospital at Kadhimiyah (TTHK) and Neurosurgical Hospital 
(NH); their sera were tested for serum total proteins (TP); the latter 
biochemical parameters were compared with those of  40 healthy 
persons. Study number II: the same patients and healthy controls 
were tested for pseudouridine measurement. Study number III: An-
other group of  30 patients with PBT were studied for TSC levels 
and were compared with 30 healthy volunteers. Study number IV: 
A third group of  26 patients with PBT, from both sexes, their sera 
were tested and measured for TE; the measurements were com-
pared to 1630 volunteers from both sexes and of  different age 
groups. The sera and brain tumor tissue samples were analysed and 
examined by appropriate methods at relevant laboratories of  the 
TTHK, NH, The Medical Research Centre (MRC) of  The College 
of  Medicine, Al-Nahrain University and the Iraqi Atomic Energy 
Committee (IAEC). Results and Discussion: The serum TP and 
PBT study: Results are shown in table 1. The serum pseudouridines 
and PBT study: Mean levels of  pseudouridine in serum of  PBT 
patients, were significantly higher (p < 0.01) than its levels in the 
(normal) controls, table 2. The TSC and PBT study:
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21. Hesalthy persons from both sexes:  age range, in 
years, 15 – 75, mean 40.5, SD ± 19.8;  TSC range 
142 – 230 mg / dl, mean 185.6 mg / dl, SD ± 
24.9, (3.7 – 5.9 mmol / l, mean 4.8 mmol / l, SD 
± 0.6), table 3.
2. Thirty persons from both sexes having periph-
eral tumors, with no clinical evidence of  brain 
tumors: age range, in years, 15 – 75, mean 54.3 
± 12.8; TSC range 90 – 220 mg / dl, 143 ± 36.3 
(2.3 – 5.7 mmol / l, mean 3.7 ± 0.9), table 4.
3. Thirty patients from both sexes with primary 
and secondary brain tumors, age range, in years, 
15 - 75, mean 41.3 ±  20.9; TSC range 140 – 284 
mg / dl, 217.6 ± 41.2 (3.6 – 7.3 mmol / l, 5.6 ± 
1.1), table 4.
Study number IV: Serum mean values (and S.D.) 
of  all measured TEs were as follow:  Se 0.045 +/- 
0.011, Zn 0.320 +/- 0.095, Cu 0.607 +/- 0.154, Fe 
0.880 +/- 0.456, Mg 13.625 +/- 3.994, Co 0.020 +/- 
0.036, Ni 0.016 +/- 0.030, Mn 0.016 +/- 0.009, Cd 
0.050 (one sample), and Cr 0.015 +/- 0.005 micro-
grams per milliliter (mcg / ml). All mean concen-
trations were consistently lower in the patients than 
healthy volunteers; both the Student’s (t) and prob-
ability (p value) tests were performed; for Se, Zn, 
Cu, Mg, Co, Ni, Mn, and Cr the p value was <0.01 
showing statistically significant results; however, for 
Fe, though the mean concentration was also lower in 
the brain tumor group, there was no statistical sig-
nificance, p > 0.05. Due to technical difficulties and 
very low concentration of  Cd, it was not measured 
in healthy volunteers; however, it was measured in 
only one patient’s serum sample; this has been dis-
carded from the study, table 5.
Conclusions: Levels of  serum TP, TC, and pseudou-
ridine are higher in patients with PBT than in healthy 
people; however, those of  serum TE are lower in the 
PBT group than healthy persons; the results of  this 
report are in keeping with those of  other research-
ers. The biochemical parameters can be an additional 
laboratory monitor in the investigation of  PBT pa-
tients; however, both the specificity and sensitivity 
need to be ascertained. To our knowledge, this was 
the first study to be performed in Iraq in the setting 
of  PBT.
INTRODUCCTION
The serum TP and PBT study 
Cancerous transformation entails major biochemical 
changes including modifications of  the energy me-
tabolism of  the cell, e.g. utilization of  glucose and 
other substrates, protein synthesis, and expression 
of  receptors and antigens. Tumour growth also leads 
to heterogeneity in blood flow owing to focal ne-
crosis, angiogenesis and metabolic demands, as well 
as disruption of  transport mechanisms of  substrates 
across cell membranes and other physiological 
boundaries such as the blood-brain barrier. All these 
biochemical, histological and anatomical changes 
can be assessed with emission   tomography, X-ray 
computed tomography , magnetic resonance imag-
ing and magnetic resonance spectroscopy; moreover, 
whereas anatomical imaging is aimed at the diagno-
sis of  brain tumours, biochemical imaging is better 
suited for tissue characterization; the latter are used 
the diagnosis of  primary brain tumours, as well as in 
follow-up (1) .Studying details of  metabolic events in 
various human cancers has attracted the interest of  
many researchers, to the extent of  using stereotactic 
microdialysis (2).
Study number II (serum pseudouridines and 
PBT)
Pseudouridine is a modified nucleoside derived from 
the degradation of  some species of  Ribonucleic acid 
(RNA), primarily transfer RNA, the level of  which 
is elevated in biological fluids of  tumor bearing sub-
jects. This study was the first to done in Iraq to mea-
sure Pseudouridine in serum of  primary brain tumor 
patients. 
Study number III (TSC and PBT) 
Total serum cholesterol (TSC) level has been found 
to vary in many physiological as well as pathologi-
cal processes. Though low TSC has been described 
in various malignancies especially those with rapidly 
proliferating cells, however, in brain tumour setting, 
the TSC value, in many patients has been found to 
be higher than normal.  
3Study number IV (The serum TE and PBT)
Micronutrients are a highly diverse array of  dietary 
components necessary to sustain health. The phys-
iologic roles of  micronutrients are as varied as their 
composition; some are used in enzymes as either 
co-factor or prosthetic groups, others are used as 
biochemical substrates or hormones, and in some 
instances, the functions are not well defined. Un-
der normal circumstances, the average daily dietary 
intake for each micronutrient required to sustain 
normal physiologic operations is measured in milli-
grams or smaller quantities. This quantification dis-
tinguishes micronutrient from macronutrients, the 
latter category encompassing carbohydrates, fats, 
and proteins, as well as the macrominerals calcium, 
magnesium, and phosphorus (3).
Fifteen trace elements have been identified as essen-
tial for health in animal studies: iron (Fe), zinc (Zn), 
copper (Cu), chromium (Cr), selenium (Se), iodine, 
fluorine, manganese (Mn), molybdenum, cobalt 
(Co), nickel (Ni), tin, silicon, vanadium, and arsenic. 
Nevertheless, only for the first 10 of  these elements 
is there compelling evidence of  essentialness in hu-
mans. Some authorities consider Zn, Cu, Mn, and 
Cr, in additions to few other cations and anions, as 
typical nutrient contents of  peripheral or central par-
enteral nutritional solution (4).
MATERIALS AND METHOD
All of  the four studies were case series studies, con-
ducted between November 2000 and October 2001 
at both TTHK and NH in Baghdad. PBT patients 
were evaluated by full medical history to exclude any 
existing systemic disease that might have targeted the 
biochemical parameters to be diagnosed, particular-
ly diabetes mellitus, liver disease, renal disease and 
chronic drug intake; otherwise the patient would 
have been excluded from the study. Patients were op-
erated upon by local staff  neurosurgeons; tumor tis-
sue samples were subjected for histological diagnosis 
by specialist neuropathologists. In the serum TP and 
PBT study, there were 107 patients suffering from 
PBT enrolled in the study; age ranged 2-75 years 
(35±19). Regarding gender, there were 56 (52.33%) 
male and 51 (47.66%) female patients. Although 
89% of  the patients were under the age of  60 years, 
however, the most affected age group was 31-40 
years (17.75%). Forty age - and sex - matched nor-
mal subjects were used as controls for serum mea-
surements. In the TSC and PBT study, it was done 
between November 2000 and April 2001. Although 
thirty patients with PBT were compared with thir-
ty healthy persons, however the thirty patients with 
peripheral tumours were mentioned in the current 
report for the sake of  comparison.  The ages ranged 
from 15 – 75 years. A serum sample was collected af-
ter 6-hour-fasting and the TSC was estimated by the 
enzymatic procedure. The mean, standard deviation 
(SD), and relevant p value have been determined and 
tabulated. 
The results: The serum TE and PBT study: This 
was a pilot study concerning ten TEs among 26 pa-
tients, 17 females and 9 males, age range 2-75 years 
[36±20.312], harboring benign or malignant brain 
tumours being operated upon at TTHK and NH 
during February till July 2001 inclusive. Estimation 
of  levels of  selenium (Se), zinc (Zn), copper (Cu), 
iron (Fe), magnesium (Mg), cobalt (Co), nickel (Ni), 
manganese (Mn), Cadmium (Cd), and chromium 
(Cr) was performed at the laboratories of  The Iraqi 
Atomic Energy Committee (IAEC) in samples of  
serum by flame / flameless atomic absorption spec-
trophotometry. The results were compared with 
those of  1630 healthy Iraqi volunteers from both 
sexes. The serum pseudouridines and PBT study: 
The same groups of  patients and healthy persons in 
the serum TP-PBT study were involved in this study. 
The samples were processed at the laboratories of  
TTHK, NH, MRC, and the IAEC. 
4RESULTS
Table 1. The mean values, and standard deviation (SD), of  TP found in the serum of  the PBT patients and 
the control groups.
 
Serum Patients Mean±SD (g/dl) Healthy Subjects Mean±SD (g/dl)   P value 
TP 9.802 ± 0.802
(All PBT patients)
 
 
6.350 ± 0.307 <0.01 
Albumin 
2.219 ± 0.530
(All PBT patients)
 
 
3.908 ± 0.724 <0.01 
Table 2. Mean concentration of  Pseudouridine in serum of  PBT patients and normal subjects.
 Fluid Patients Mean±SD (n mol/ml) Control subjects Mean±SD (n mol/ml) P value 
Serum 3.9023±0.69 2.19±0.38 <0.01  
Table 3. TSC level in healthy controls. 
Mean age in years ± SD      40.5  ±19.8 
Mean TSC in mg / dl (mmol / l) ± SD 185.6 ± 24.9 (4.8 ± 0.6)
 
 
DISCUSSION
Study number I
A highly significant increase in TP levels in serum of  
PBT patients was noticed when compared to those 
normal subjects (Table 1). The result shows a statis-
tical significance, p value < 0.01.
This increase could be explained on the basis that the 
whole body of  cancer patients is engaged in protein 
synthesis of  various forms like: C-reactive proteins, 
tumor markers, enzymes, and immunoglobulins and 
other proteinous material. Our results are in agree-
ment with Fiandra et al (5) who found that patients 
with neoplasm had higher values of  total protein 
(P<0.01). In addition, patients with oral squamous 
cell carcinoma had also markedly increased total pro-
tein concentrations (6, 7). Nagashima and Schreiber (8) 
grouped several plasma proteins as acute phase re-
actant (APR), which significantly rise during inflam-
mation and neoplasm. Wicher (9) on the other hand, 
found that the increase in synthesis of  APR is ac-
companied by a decrease in the synthesis of  preal-
bumin, albumin and transferrin, which are so called 
negative APR. Inflammatory tissue lesions generally 
induce changes in the concentrations of  various se-
rum proteins. The APRs may be increased, albumin 
may be decreased and the immunoglobulin produc-
tion may be enhanced. 
 
5Table 4. TSC in brain tumour group (primary and secondary). BS=brain secondaries.
Histological type Age in years 
TSC mg per dl 
(mmol / l) Histological type 
Age in 
years 
TSC mg per dl 
(mmol / l) 
 
 
 
Anaplastic 
astrocytoma 
42 260 (6.7) Cerebellar astrocytoma 40 185 (4.8) 
26 225 (5.8)  
 
 
 
 
 
Medulloblastoma 
15 284 (7.3) 
29 275 (7.1) 31 204 (5.3) 
56 255 (6.6) 16 140 (3.6) 
40 285 (7.3) 16 175 (4.5) 
59 160 (4.1) 40 185 (4.8) 
70 195 (5) 16 195 (5) 
16 168 (4.3) 16 180 (4.7) 
Gliomas of corpus 
callosum 24 245 (6.3)  Meningioma 
46 190 (4.9) 
 
 
Cerebello-pontine 
angle 
schwannoma 
60 275 (7.1) 75 235 (6.1) 
47 247 (6.4) Craniopharyngioma 52 275 (7.1) 
19 235 (6.1) B S of  bronchogenic carcinoma 75 225 (5.8) 
55 260 (6.7) B S of  nasopharyngeal carcinoma 34 185 (4.8) 
70 205 (5.3) B S of  breast carcinoma 73 210 (5.4) 
Choroids plexus 
papilloma 15 200 (5.2) B S  of  gastric carcinoma 65 170 (4.4) 
Total: Mean age in years ± SD 41.3 ± 20.9 
Total: Mean TSC in mg / dl (mmol / l) ± SD 217.6 ± 41.2 (5.6 ± 1.1)  
Table 5. TEs measurements in sera of  healthy volunteers and patients with PBT (mcg/ml).
TE Serum values in healthy volunteers 
Serum values in brain 
tumours patients Student test (t) 
Probability test 
(p value) 
Se 0.085 –0.190  (0.099) 0.010-0.066 (0.045 ± 0.011) - 24.050 < 0.01 
Zn 0.550 –1.500  (0.980) 0.140-0.560 (0.320 ± 0.095) - 33.984 < .01 
Cu 0.600 – 1.850 (1.410) 0.360-0.930 (0.607 ± 0.154) - 25.545 < 0.01 
Fe 0.700 – 1.200 (1.010) 0.180-1.800 (0.880 ± 0.456) - 1.397 > 0.05 
Mg 15.000 – 22.000 (16.000) 5.500-20.000 (13.625 ± 3.994) - 2.913 < 0.01 
Co 0.020 – 0.060 (0.050) 0.007-0.190 (0.020 ± 0.036) -  4.083 < 0.01 
Ni 0.015 – 0.056(0.040 ) 0.005-0.160 (0.016 ± 0.030) -  3.919 < 0.01 
Mn 0.020 – 0.040 (0.030) 0.010-0.050 (0.016 ± 0.009) -  6.025 < 0.01 
Cr 0.020 – 0.075 (0.055) 0.008-0.030 (0.014 ± 0.005) -  39.192 < 0.01 
 
6The increase in total protein concentrations, in this 
study, indicated that synthesis of  APR proteins had 
exceeded the synthesis of  negative APR, this imbal-
ance leads to a marked increase in TP levels. Reduced 
serum albumin concentration is a common finding 
in patients with neoplastic diseases. Hypoalbuminae-
mia can appear early in the course of  the disease, 
and indeed it may occur despite normal nutrition and 
even without effusion, protein loss or evident clinical 
signs of  liver damage (10).
The presence of  hypoalbuminaemia has been wide-
ly confirmed in the malignant lymphomas (10), pros-
tatic cancer (11), melanoma (12), colorectal cancer (13) 
and leukemia (14). It is well established that the acute 
phase reaction, usually involved interleukins, tumor 
necrosis factor (TNF), and C-reactive proteins caus-
ing a reduction in the concentration of  albumin, is 
associated with the risk and development of  cancer 
(15).
However, it has been shown that TNF may increase 
the permeability of  the microvasculature, thus allow-
ing an increased trans-capillary passage of  albumin 
(16) and hence a lowering of  the serum albumin con-
centrations.
The present study, like other researchers’ findings, 
demonstrated a significant decrease in albumin con-
centration in serum of  patients with PBT (2.21± 0.53 
g/dl) in comparison to normal group (3.90±0.72 g/
dl) with statistical significance (p < 0.01) as seen in 
table 1. Also, in this study, TP have been found to be 
more in tissues of  malignant PBT than in the benign 
ones with a statistical significance, p <0.01. Using 
spectrophotometry to estimate the activity of  gluta-
thione peroxydase, glutathione reductase and super-
oxide dismutase in the brain tumours, the statistical 
analysis of  their study revealed significant increase 
of  enzymes within the brain tumours in comparison 
to the healthy brain tissue. Therefore, we think, this 
may also contribute to the increase in local tumour 
tissue protein (17).
Saadoun et al (18, 19) have found that aquaporin 1 and 
4, conserved water channel proteins, are present 
with increased expression in microvascular endo-
thelium and reactive astrocytes of  astrocytomas and 
metastatic adenocarcinomas. Therefore, it is also 
our opinion that these may also contribute to the 
increased proteins in brain tumours (18, 19). Vascular 
endothelial growth factor (VEGF), a key regulatory 
protein in neoangiogenesis, is strongly expressed in a 
variety of  PBT, particularly malignant gliomas. Their 
findings indicated that immunoreactive VEGF was 
produced at the tumour site and abundantly released 
into the cyst fluid of  primary and metastatic brain 
tumours. Interestingly, this abundant local release 
was not reflected in serum VEGF levels, even in the 
case of  very high VEGF concentrations in tumour 
cysts. Thus, VEGF may be biologically relevant for 
the formation of  tumour cysts in brain tumours and 
correlates with local disease progression (20).
Studying the measurements of  many biochemical 
items, including proteins, as far as the possible role 
of  blood-brain barrier disruption in cyst formation 
in craniopharyngioma, researchers have proved the 
hypothesis of  blood-brain barrier impairment in 
such patients and that the pathogenesis of  cranio-
pharyngiomal cyst appears to be much more akin to 
those described for cysts accompanying other brain 
tumours than it was believed earlier (21).
Study number II
In this study, a rapid, efficient and precise method 
for analysis of  pseudouridine in   serum of  patients 
and healthy individuals was employed to evaluate the 
usefulness of  serum and salivary pseudouridine as 
a diagnostic and prognostic biochemical marker for 
PBT patients. Numerous studies (22) have document-
ed the occurrence of  increased levels of  modified 
nucleosides in the biological fluids of  cancer patients. 
Of  these nucleosides, pseudouridine is the most fre-
quently and most significantly elevated. Pseudouri-
dine is produced as a result of  degradation of  tRNA, 
since it’s not metabolized, nor incorporated in tRNA 
formation, consequently, elevated level of  pseudou-
ridine have been considered to reflect the rate of  
tRNA turnover (22), so that an increase in pseudou-
ridine concentration could be possibly useful as a 
mean of  determining tumor response to therapy and 
a valuable marker for monitoring the course of  pa-
tient during treatment. It has been found that the lev-
el of  pseudouridine excretion drops down to normal 
7after commencement of  chemotherapy and remains 
normal as long as the patient is in remission, this was 
found in Burkit’s lymphoma and T-acute lymphoma 
leukemia (23). This study has shown that pseudouri-
dine was found to be significantly elevated in serum 
of  PBT patients. The use of  nucleosides (particularly 
pseudouridine) as tumors marker, primarily for mon-
itoring the progression of  tumors and their response 
to treatment, has been proposed; however, the bio-
logical basis of  the phenomenon has not been clar-
ified, nor has the specificity or prediction value for 
cancer diagnosis been studied extensively (23, 25).
Study number III 
Reduced blood cholesterol levels were reported in 
patients with a variety of  malignant peripheral tu-
mors (26, 29). This fact is likely related to increased 
cholesterol demand by proliferating tumor cells 
(1), or to nutritional status (28), though others think 
that the abnormality is a common feature of  both 
hematological and solid tumors and is not entirely 
explained by poor nutrition (30). The question arises 
whether this ‘tumor-associated hypocholesterolae-
mia occurs also in patients with brain tumors, and, 
if  it does not, whether its absence can be related to 
the location of  the tumors. Grieb et al (26) have com-
pared fasting serum total cholesterol levels among 
three groups of  patients: 52 patients with gliomas, 
56 patients with symptomatic metastatic brain tu-
mors, and 50 patients harboring malignant tumors 
of  peripheral location but showing no clinical signs 
of  brain metastases. Patients in the last group, de-
spite being on an average more age-advanced, had 
lower total serum cholesterol levels than either the 
patients with gliomas, or the patients with brain me-
tastases. No difference in the cholesterol levels was 
found between the two latter groups, and a majority 
of  these patients had borderline or elevated choles-
terol levels. This apparent absence of  ‘tumor-asso-
ciated hypocholesterolaemia in brain tumor patients 
may be related to either brain tumors’ ability to syn-
thesize cholesterol de novo and their reduced depen-
dence on peripheral cholesterol supply, the existence 
of  brain tumor-blood barrier, effect of  medications 
used to counteract brain edema and seizures, or a 
combination of  these factors (28).
In her study, Al-Azzawi (31) has found that the mean 
value of  TSC in 314 Iraqi healthy males and females, 
172.4 ± 29.5 mg per dl (28). Comparing these values 
to that shown in Table 3, the healthy control, in this 
study, have a marginally higher level than those in 
Al-Azzawi’s study (31). This is probably due to a lower 
number of  patients, higher age inclusion, and that 
this study was performed in colder weather (autumn, 
winter, and early spring seasons). Patients with brain 
tumours have higher overall mean (and few abso-
lute values) of  TSC than both the healthy controls 
and those harboring peripheral tumours (32, 34). This 
shows clearly the absence of  tumour-associated hy-
pocholesterolaemia in brain tumor patients. This 
finding is consistent with Grieb et al’s study (26). 
Many explanations can be introduced but need more 
sophisticated methods for confirmation; it may be 
attributed to brain tumour cells’ ability to synthesize 
cholesterol de novo and their reduced dependence 
on peripheral cholesterol supply, also the existence 
of  brain tumour-blood-brain barrier can contribute 
to this reduced dependence. However, interestingly, 
researchers have found an increased concentration 
of  cholesterol esters up to 100 times (0.1-10 mu-
mol/g) in both tumour-tissue and surrounding areas 
compared with control material (< 0.1 mumol/g); 
the analyses also demonstrated that cholesterol esters 
in tumour tissue emanated mainly from serum [25]. 
The cholesterol concentrations were significantly 
lower in tumour tissue compared with surrounding 
areas as expected. These results indicate that tumour 
cell proliferation utilizes serum derived cholesterol 
esters presumably carried by LDL particles (29).  
We, also, agree with Laurence et al that we should 
take into account the drugs used in brain tumour pa-
tients that counteract brain oedema and seizures like 
diuretics used to reduce intracranial pressure (35). 
Some studies have shown an increased synthesis of  
cholesterol by tumour cells in leukaemic patients 
but these cells were cholesterol deficient; these find-
ings raise the possibility that proliferating cells in 
malignant blood diseases display abnormal choles-
terol metabolism and are depressed as regards the 
negative feedback regulation normally exerted by 
LDL-receptors which normally inhibit endogenous 
8synthesis of  cholesterol. But what might happen in 
brain tumour is that the increased rate of  endoge-
nous synthesis of  cholesterol by tumour cells with 
an increase in the LDL-receptor negative feedback 
mechanism which might be due to the presence of  
brain tumour-blood-brain barrier. 
Changes in the content and composition of  lipids 
in brain tumours of  different degree of  malignancy 
are still the subject of  numerous scientific studies. 
It is known that in developing brain tumours struc-
tural and functional changes of  its cells, take place, 
in which lipids play a crucial role. Statistical analy-
sis showed significant decrease of  phospholipids 
(elements stabilizing cell membranes) in tumours in 
comparison to their adjacent areas (Wilcoxon’s test: 
p < 0.05). At the same time in tumours an increase 
of  level of  plasmalogens took place: phosphatidyl-
choline, phosphatidylethanolamine typical elements 
of  malignant tumours, responsible for cross cell 
membrane transportation processes. Changes in 
the level of  lipids, and phospholipids in particular, 
in glioblastoma in comparison to adjacent areas can 
indicate the pathological processes in cells of  these 
tumours (36).
Regarding the synthesis and regulation of  neuroste-
roids in human brain, researchers have examined the 
ability of  human brain cells to synthesize steroids 
from a radiolabeled precursor and the mRNA and 
protein expression of  key components of  peripheral 
steroidogenic machinery. Oligodendrocytes are the 
source of  pregnenolone in human brain. Human 
astrocytes do not synthesize radiolabeled pregneno-
lone, nor do human neurons. These results indicate 
that human brain makes steroids in a cell-specific 
manner and suggest that dehydroepiandrosterone 
synthesis can be regulated by intracellular free rad-
icals (37).
An important feature of  malignant transformation 
of  tumours is the loss of  cholesterol feedback inhi-
bition mechanism (cholesterol-feedback lesion) that 
regulates mevalonate pathway recognized to play a 
crucial role in cellular growth, death and differentia-
tion. Recently, it was shown that Receptor-C(k)-de-
pendent signaling regulates genes involved in main-
taining cellular cholesterol homeostasis through a 
transcription factor sterol response element binding 
protein (SREBP) having affinity for sterol regulato-
ry element (SRE) present in the promoter region of  
these genes. The present study revealed that CNS 
tumours exhibit overexpression of  Receptor-C (k) 
gene product which was accompanied by their in-
ability to express SREBP gene product and this phe-
nomenon has the inherent capacity to initiate the 
cholesterol feedback lesion in these tumours. Based 
upon these and our earlier studies, we propose for 
the first time that this loss of  cholesterol feedback 
control may be responsible for the initiation of  these 
tumours (38).
Study number IV 
Associations between diet and central nervous sys-
tem tumours (CNS) in humans remain hypothetical 
(39). It is believed that the consumption, and endoge-
nous production of  N-nitroso compounds and their 
precursors might increase brain tumour risk (40). On 
the other hand, the consumption of  orange juice and 
vitamin supplements (which contain antioxidant sub-
stances such as ascorbic acid which inhibit endoge-
nous nitrosation activity) has been associated with 
reduced risk of  childhood CNS tumours (41-42). Most 
dietary epidemiologic studies of  CNS tumours, how-
ever, have used poor measures of  intake and have 
been too small to detect significant risks. Burch et al 
suggested a protective effect of  fruit but not vege-
tables (43). Preston-Martin et al suggested that citrus 
fruits were protective of  meningioma but the odd ra-
tio was not statistically significant (44). A prospective 
study of  Seventh-Day Adventists showed discrepant 
and non-significant associations with dietary items 
(45). A case-control study in Germany detected an in-
creased glioma risk associated with the consumption 
of  ham, processed pork and fried bacon, but no as-
sociation with endogenous N-nitosation, or with the 
intake of  vitamin C, or fruit and vegetables (46). In 
an Australian study, no increase in risk of  glioma or 
meningioma was found with the regular consump-
tion of  food rich in N-nitroso precursors, nor were 
any decrease in risk associated with the regular use 
of  foods and supplements containing endogenous 
nitrosation inhibitors (47). Similarly, the results of  a 
9case-control study of  maternal diet during pregnan-
cy and risk of  astrocytoma, the most common child-
hood brain tumour, was conducted by the Children’s 
Cancer Group, provided a limited support for the 
nitrosamine hypothesis and concluded that a future 
research should investigate the effect of dietary com-
ponents not assessed in this study (48).
The biochemical functions of  TEs have not been 
as well characterized as those for the vitamins, but 
most of  their functions appear to be as components 
of  prosthetic groups or as cofactors for a number 
of  enzymes. Determination of  essential TEs status 
is problematic except for iron, selenium, and iodine. 
The vanishingly low concentrations of  these ele-
ments in body fluids and tissues, the fact that blood 
levels frequently do not correlate well with levels in 
the target tissues, and the fact that functional tests 
cannot be devised until biochemical functions are 
better understood preclude an accurate and conve-
nient laboratory method of  assessment for most of  
the TEs (49). However, estimation of  TEs in serum, 
CSF, and brain tumour tissue in patients harboring 
brain tumours and experimental animal brain tu-
mour models, whether by flame / flameless  atom-
ic absorption spectrophotometry  or instrumental 
neutron activation analysis techniques have attracted 
many researchers (46, 51). 
During 1984 –1990, El-Yazigi et al (49, 52) conducted 
four different studies estimating values of  20 TEs in 
CSF of  control persons and patients with cerebral 
(both benign and malignant), non-cerebral tumours 
(e.g., leukaemia), and some neurological disorders. 
They found that most of  the TEs were lower in pa-
tients with neoplasia, especially malignant tumours, 
than in the control group. However, silver and lead 
values were higher in the malignant brain tumour 
group, concentrations of  arsenic in CSF of  patients 
with non-brain malignant tumors were significant-
ly (p less than 0.05) higher than in the controls, the 
ratio for mean CSF concentration of  arsenic in pa-
tients with non-brain tumors/control patients was 
2.9, and that differences in the concentrations of  Fe, 
lithium, or molybdenum among the various groups 
were nonsignificant (53, 54). However, although we have 
measured the concentration of  TEs in the CSF of  
our patients, we have no values for the CSF among 
healthy volunteers or appropriate control group for 
comparison. Moreover, not all TEs in the El-Yasigi 
et al’s study were assayed by us.
This study has shown that Se mean level, like oth-
ers, is lower in the brain tumour patients than in the 
healthy volunteers (Table 5) (55, 56). This finding is in 
accord with that of  other researchers (53). Some of  
the latter could demonstrate the inhibitory effect of  
Se on rat glioma and activity of  glutathione peroxi-
dase after development of  tumors was significantly 
higher in the high Se group at 18 and 30 days. In 
some studies, Se has exhibited an antiproliferative 
effect on human glioma cell lines (and induced the 
typical ladder pattern of  DNA fragmentation com-
monly found in apoptosis), which were prevented by 
catalase. These findings demonstrate that selenium 
may induce, by apoptosis, cell death of  human gli-
oma cell lines, which are resulting from free radical 
oxygen forming (55, 56). However, others have even 
tried giving Se supplements to the diet of  patients 
with brain tumours but without convincing useful 
result. Similar to Se, Zn has been found to be lower 
in the brain tumour group than the healthy people 
(Table 5). Zn has been found to selectively inhibit, 
in vitro, human glioblastoma cell multiplication but 
at the same concentrations do not inhibit astrocyte 
multiplication (57, 62). 
Sciaudone et al (63) have demonstrated that chela-
tion of  Zn amplifies induction of  growth hormone 
mRNA levels in cultured rat pituitary tumour cells 
(63). Circulating Zn levels have been found to be low 
in patients with pituitary tumours such as prolacti-
nomas (64). However, other researchers indicated that 
orally administered Zn to rat with experimental brain 
tumour had a cocancerogenic (promotion) effect of  
Zn in neurooncogenesis of  the rat (65, 66). Copper ion 
has been coupled with tumour angiogenesis both in 
human and animal model brain tumours; they found 
that Cu ions promote angiogenic phenomena and 
that Cu depletion could reduce brain tumour growth 
by angiosuppression (67).
Microvascular proliferation, a hallmark of  malignant 
brain tumors, represents an attractive target of  anti-
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cancer research, especially because of  the quiescent 
nonproliferative endothelium of  the normal brain. 
Cerebral neoplasms sequester copper, a trace metal 
that modulates angiogenesis. Using a rabbit brain tu-
mor model, normocupremic animals developed large 
vascularized VX2 carcinomas. By contrast, small, cir-
cumscribed, relatively avascular tumors were found 
in the brains of  rabbits copper-depleted by diet and 
penicillamine treatment. Metabolic and pharmaco-
logic withdrawal of  copper suppresses intracerebral 
tumor angiogenesis; angiosuppression is a novel bi-
ologic response modifier for the in situ control of  
tumor growth in the brain (68).
There was a very interesting finding by Kaiser et al: 
The copper content of  astrocytomas and glioblas-
tomas was investigated by the cuproin-method; the 
peritumoral tissue of  glioblastomas contained more 
copper than the tumour tissue itself. In astrocyto-
mas, on the other hand, more copper was detected 
in the central parts of  the tumours (69). Brem et al and 
Yoshida et al (70, 72) therefore, suggested manipulating 
pharmacological and metabolic cellular microenviro-
ment represent a novel useful therapeutic approach 
in the treatment of  brain cancer.
Many studies have investigated not only the levels of  
TEs, but also the role(s) of  their dependent enzymes 
(73). Rao et al and others (74) have found a significant 
decrease in red blood cells (RBC) glutathione reduc-
tase (GRx) and superoxide dismutase (SOD) activi-
ty in most types of  brain tumor cases. Patients with 
acoustic neurinoma showed a significant reduction 
in selenium-dependent glutathione peroxidase (Se-
GPx) activity. A decrease in catalase activity was seen 
in most of  the brain tumor patients but remained 
statistically insignificant when compared to controls. 
A significant increase in plasma ceruloplasmin con-
centration was observed in patients with glioma (75). 
These enzymes were also studied in 27 post-treat-
ment cases. GRx activity returned to normal levels in 
these patients. RBC SOD and plasma ceruloplasmin 
levels showed a tendency to return to normal. Hence, 
a marked decrease in the antioxidant enzymes may 
have a role in the genesis of  considerable oxidative 
stress in patients with brain tumors (69, 70).
Some investigators have linked the levels of  these 
TEs-dependent enzymes with the prognosis of  some 
types of  brain tumours. For example, Kurisaka et al 
using a monoclonal antibody against human copper- 
and zinc-SOD, have exhibited abundant SOD in 
tumors from patients with poor outcomes and little 
SOD in patients with good outcomes. Their results 
had suggested, they stated, that resistance to adjuvant 
therapy depends on the amount of  SOD in tumor 
tissues, and since the effects of  adjuvant therapies 
for medulloblastomas depend on the production of  
free oxygen radicals, so if  tumor cells contained a 
free radical scavenger such as SOD, the effects of  
adjuvant therapy might be reduced. Measurement of  
SOD in tumor tissues they concluded, might be use-
ful as a prognostic indicator for medulloblastoma (76).
CONCLUSIONS
A highly significant increase in TP levels in serum of  
PBT patients was noticed when compared to those 
normal subjects. The result shows a statistical signifi-
cance, p value <0.01. This study has also shown clear-
ly the absence of  tumour-associated hypocholestero-
laemia in patients harboring brain tumour; on the 
contrary, there is elevation of  TSC in the majority of  
patients although some are younger due, probably, to 
an increased synthesis of  cholesterol by tumour cells 
themselves and/or to the drugs in the treatment of  
seizures and raised intracranial pressure as well as by 
other means as mentioned above. Therefore, we may 
conclude, although can be too early, that when the 
clinician is confronted with brain tumours in clinical 
practice and gets confused whether the intracranial 
lesion is a primary or metastatic tumour, an estima-
tion of  TSC level may help in dissolving the dilem-
ma!. Also, we recommend that more future work is 
needed to correlate this relation between TSC and 
brain tumour in the context of  prognosis and the 
response to treatment, and in case any concomitant 
dietary modifications or pharmacological therapy to 
correct such biochemical abnormality will have any 
consequences on the outcome. 
TEs can be used as biochemical parameters in the 
investigation of  various disease processes including 
brain tumours, though the artiological association 
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between the latter and TEs need to be convincingly 
conclusive at a universal scale. They should be esti-
mated in the common food stuff  consumed by the 
Iraqis in order to establish the approximate intake 
to help directing health authorities to educate peo-
ple regarding their daily allowances, intake and/or if  
any supplements are needed to be given to certain 
age groups such as growing children and pregnant 
mothers. Also, the normal values of  TEs in various 
biological fluids of  healthy people should be assayed 
and established. Future studies should be performed 
on a larger group of  tumour victims an expanded to 
include the role of  other TEs in this context. Though 
we have discussed only few TEs in the context of  
brain neoplasia, we think that investigations should 
be continued in this field to include many other TEs 
and their dependent enzyme system(s) in the aeti-
ology, prognosis, and/or therapeutic approaches to 
brain neoplasia.
 
Many levels of  pseudouridine in serum of  PBT pa-
tients, were significantly higher (p<0.01) than its lev-
els in normal and they can be an extra tool in the 
investigation of  PBT patients; particularly, the anal-
ysis by HPLC technique is a sensitive, accurate and 
specific one. However, both the specificity and sen-
sitivity need to be ascertained. We think that in or-
der to decide upon the “Specificity and Sensitivity” 
of  the findings in relation to brain tumours, as well 
as in case there has been any deleterious effect on 
the body health, in any, we need to repeat the study 
upon a large group of  patients with brain tumours 
compared to control “healthy” group of  persons, 
randomly selected from the community, from both 
sexes, and of  different age groups stretching over 
significant time period, i.e. for many years. Howev-
er, the latter time period duration may have certain 
limitation, especially so in the case of  patients with 
highly malignant PBT, e.g. glioblastoma multiforme 
who have relatively short survival after establishing 
the histological diagnostic nature of  the disease, de-
spite the modality of  treatment adopted. 
However, we need:
1. The intention to do this.
2. Researcher (s).
3. Patients harboring PBT.
4. Other logistic support: laboratory services, 
materials and well trained personnel. And, 
5. Finance. 
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